Chicago Atlantic Group Reports 14.5% Vireo Stake After Fluent Credit Equitization
VREOF is trading near its 52-week low of $6.4 (4.4% above the low).
Summary
Chicago Atlantic's funds now hold 7,470,203 Vireo shares, or 14.5%, after converting about $29.2M of Fluent debt into equity that rolled into Vireo's acquisition of Fluent. The group also holds a convertible note and expects more shares from the pending Ohio deal.
Key Events · Ownership and Investor Activity · VREOF
-
Chicago Atlantic Reports 14.5% Stake
The Chicago Atlantic group beneficially owns 7,470,203 Vireo subordinate voting shares, or 14.5% of the class, per Amendment No. 3 to its Schedule 13D.
-
Debt Converted Into Equity
Affiliates received 3,884,062 Vireo shares after Fluent issued 1,651,951,654 shares to them in satisfaction of about $29,203,572.88 of debt, exchanged at 0.002351197 per share in the November 9, 2026 arrangement. No cash was paid.
-
Convertible Note and Warrants Overhang
CAOF holds a $10M 2025 convertible note with $8.8M outstanding, convertible into 502,800 shares at $18.75 post-split; CAOP holds 2023 warrants for 163,152 shares at $4.35, expiring April 28, 2028.
-
More Shares Expected From Ohio Deal
Affiliates are expected to receive an aggregate of 7,617,297 shares in the previously announced Ohio transaction, which would further increase the group's position.
Analysis · VREOF · Life Sciences
Chicago Atlantic's funds converted roughly $29.2M of Fluent debt into equity and, through Vireo's acquisition of Fluent, ended up with 7,470,203 shares — 14.5% of Vireo on a fully diluted basis. That makes the lender-turned-holder one of Vireo's largest shareholders, and its CEO, John Mazarakis, already runs Vireo's board. The group also holds a $10M convertible note ($8.8M outstanding, 502,800 shares at $18.75) and expects another 7,617,297 shares from the pending Ohio transaction, so the stake is likely to grow. The shares received are locked up, which limits near-term selling pressure, but the conversion of debt into stock is real dilution to existing holders.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VREOF was trading at $6.68 on OTC in the Life Sciences sector, with a market capitalization of approximately $344.6M. The 52-week trading range was $6.40 to $21.76. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.